Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Metals in our minds: therapeutic implications for neurodegenerative disorders.

Doraiswamy PM, Finefrock AE.

Lancet Neurol. 2004 Jul;3(7):431-4. Review.

PMID:
15207800
2.

Clioquinol: review of its mechanisms of action and clinical uses in neurodegenerative disorders.

Bareggi SR, Cornelli U.

CNS Neurosci Ther. 2012 Jan;18(1):41-6. doi: 10.1111/j.1755-5949.2010.00231.x. Epub 2010 Dec 27. Review.

PMID:
21199452
3.

Iron chelating strategies in systemic metal overload, neurodegeneration and cancer.

Gumienna-Kontecka E, Pyrkosz-Bulska M, Szebesczyk A, Ostrowska M.

Curr Med Chem. 2014;21(33):3741-67. Review.

PMID:
25005181
4.

Therapeutic redistribution of metal ions to treat Alzheimer's disease.

Crouch PJ, Barnham KJ.

Acc Chem Res. 2012 Sep 18;45(9):1604-11. Epub 2012 Jun 29.

PMID:
22747493
5.

Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.

Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW; PBT2-201-EURO study group.

Lancet Neurol. 2008 Sep;7(9):779-86. doi: 10.1016/S1474-4422(08)70167-4. Epub 2008 Jul 30. Erratum in: Lancet Neurol. 2009 Nov;8(11):981.

PMID:
18672400
6.

Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.

Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL.

Arch Neurol. 2003 Dec;60(12):1685-91. Erratum in: Arch Neurol. 2004 May;61(5):776.

PMID:
14676042
7.

Metal complexing agents as therapies for Alzheimer's disease.

Bush AI.

Neurobiol Aging. 2002 Nov-Dec;23(6):1031-8. Review.

PMID:
12470799
8.

Metal protein attenuating compounds for the treatment of Alzheimer's disease.

Sampson E, Jenagaratnam L, McShane R.

Cochrane Database Syst Rev. 2008 Jan 23;(1):CD005380. doi: 10.1002/14651858.CD005380.pub3. Review. Update in: Cochrane Database Syst Rev. 2012;5:CD005380.

PMID:
18254079
9.

Clioquinol reduces zinc accumulation in neuritic plaques and inhibits the amyloidogenic pathway in AβPP/PS1 transgenic mouse brain.

Wang T, Wang CY, Shan ZY, Teng WP, Wang ZY.

J Alzheimers Dis. 2012;29(3):549-59. doi: 10.3233/JAD-2011-111874.

PMID:
22269164
10.

Effects of clioquinol on metal-triggered amyloid-beta aggregation revisited.

Mancino AM, Hindo SS, Kochi A, Lim MH.

Inorg Chem. 2009 Oct 19;48(20):9596-8. doi: 10.1021/ic9014256.

PMID:
19817493
11.

Therapeutic treatment of Alzheimer's disease using metal complexing agents.

Price KA, Crouch PJ, White AR.

Recent Pat CNS Drug Discov. 2007 Nov;2(3):180-7. Review.

PMID:
18221229
12.
13.

Involvement of environmental mercury and lead in the etiology of neurodegenerative diseases.

Monnet-Tschudi F, Zurich MG, Boschat C, Corbaz A, Honegger P.

Rev Environ Health. 2006 Apr-Jun;21(2):105-17. Review.

PMID:
16898674
14.

Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease.

Grossi C, Francese S, Casini A, Rosi MC, Luccarini I, Fiorentini A, Gabbiani C, Messori L, Moneti G, Casamenti F.

J Alzheimers Dis. 2009;17(2):423-40. doi: 10.3233/JAD-2009-1063.

PMID:
19363260
15.

Alzheimer's disease & metals: therapeutic opportunities.

Kenche VB, Barnham KJ.

Br J Pharmacol. 2011 May;163(2):211-9. doi: 10.1111/j.1476-5381.2011.01221.x. Review.

16.

New therapeutic strategy for Parkinson's and Alzheimer's disease.

Esposito E, Cuzzocrea S.

Curr Med Chem. 2010;17(25):2764-74. Review.

PMID:
20586718
17.

Amyloid-beta metal interaction and metal chelation.

Cuajungco MP, Frederickson CJ, Bush AI.

Subcell Biochem. 2005;38:235-54. Review.

PMID:
15709482
18.

Redox-active metals, oxidative stress, and Alzheimer's disease pathology.

Huang X, Moir RD, Tanzi RE, Bush AI, Rogers JT.

Ann N Y Acad Sci. 2004 Mar;1012:153-63. Review.

PMID:
15105262
19.

Metal and inflammatory targets for Alzheimer's disease.

Rogers JT, Lahiri DK.

Curr Drug Targets. 2004 Aug;5(6):535-51. Review.

PMID:
15270200
20.

Supplemental Content

Support Center